Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Prognostic Artificial Intelligence Scores and Outcomes in Nonmetastatic Prostate Cancer
0
Zitationen
2
Autoren
2025
Jahr
Abstract
JCO PO author Dr. Timothy Showalter at Artera and University of Virginia shares insights into his JCO PO article, “Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer” . Host Dr. Rafeh Naqash and Dr. Showalter discuss how multimodal AI as a prognostic marker in nonmetastatic castration-resistant prostate cancer may serve as a predictive biomarker with high-risk patients deriving the greatest benefit from treatment with apalutamide.
Ähnliche Arbeiten
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 · 5.698 Zit.
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 · 5.450 Zit.
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 · 4.542 Zit.
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
1998 · 4.488 Zit.
Abiraterone and Increased Survival in Metastatic Prostate Cancer
2011 · 4.368 Zit.